MREO vs MRKR

Mereo BioPharma Group plc vs Marker Therapeutics, Inc. — Valuation Comparison 2026

MREO

Biotechnology
Mereo BioPharma Group plc
Quality
5.0
out of 10
Value Trap
12
SAFE
Price
$0.34
Last close
Models
8/13
Active
VS

MRKR

Biotechnology
Marker Therapeutics, Inc.
Quality
6.1
out of 10
Value Trap
18
SAFE
Price
$1.51
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType MREO Fair ValueMREO Upside MRKR Fair ValueMRKR Upside
Bayesian DCF Intrinsic $0.17 -50.7% $0.89 -40.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.85 +146.5% $2.10 +39.1%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for MREO vs MRKR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MREO vs MRKR — Which Stock Is More Undervalued?

MRKR scores higher with a 6.1/10 quality rating vs MREO's 5.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Mereo BioPharma Group plc (MREO) and Marker Therapeutics, Inc. (MRKR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MREO currently trades at $0.34 with a QOC of 5.0/10, while MRKR trades at $1.51 with a QOC of 6.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).